Table 3 Dengue antibody response post-dose 3 by baseline FV status
Group 1 (N = 117) | Group 2 (N = 119) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
FV Seropositivea (N = 63) | FV Seronegativeb (N = 54) | FV Seropositivea (N = 65) | FV Seronegativeb (N = 54) | |||||||||
n | GMT (95% CI) | Seropositive % | n | GMT (95% CI) | Seropositive % | n | GMT (95% CI) | Seropositive % | n | GMT (95% CI) | Seropositive % | |
Serotype 1 | ||||||||||||
Baseline | 63 | 5.73 (4.72–6.94) | 3.2 (0.4–11.0) | 54 | 5.00 (NC) | 0.0 (0.0–6.6) | 65 | 5.23 (4.96–5.53) | 4.6 (1.0–12.9) | 54 | 5.00 (NC) | 0.0 (0.0–6.6) |
28 days post-dose 3 | 51 | 15.6 (10.6–23.0) | 54.9 (40.3–68.9) | 42 | 13.9 (9.49–20.4) | 50.0 (34.2–65.8) | 59 | 17.2 (12.7–23.3) | 61.0 (47.4–73.5) | 49 | 14.4 (10.1–20.7) | 51.0 (36.3–65.6) |
6 months post-dose 3 | 49 | 14.8 (10.0–21.7) | 53.1 (38.3–67.5) | 39 | 11.7 (8.04–17.1) | 41.0 (25.6–57.9) | 58 | 10.3 (7.85–13.4) | 36.2 (24.0–49.9) | 46 | 7.63 (6.16–9.46) | 28.3 (16.0–43.5) |
12 months post-dose 3 | NA | NA | 55 | 9.35 (7.50–11.7) | 40.0 (27.0–54.1) | 44 | 7.45 (5.87–9.47) | 25.0 (13.2–40.3) | ||||
Serotype 2 | ||||||||||||
Baseline | 63 | 5.35 (4.67–6.13) | 1.6 (0.0–8.5) | 54 | 5.00 (NC) | 0.0 (0.0–6.6) | 65 | 5.42 (4.93–5.96) | 4.6 (1.0–12.9) | 54 | 5.00 (NC) | 0.0 (0.0–6.6) |
28 days post-dose 3 | 52 | 60.0 (39.4–91.4) | 84.6 (71.9–93.1) | 42 | 42.1 (27.9–63.4) | 83.3 (68.6–93.0) | 59 | 68.1 (48.9–94.7) | 94.9 (85.9–98.9) | 49 | 51.4 (32.8–80.6) | 79.6 (65.7–89.8) |
6 months post-dose 3 | 49 | 52.5 (32.1–85.8) | 79.6 (65.7–89.8) | 39 | 38.1 (21.7–67.0) | 69.2 (52.4–83.0) | 58 | 53.0 (37.4–75.2) | 91.4 (81.0–97.1) | 46 | 26.0 (17.2–39.3) | 67.4 (52.0–80.5) |
12 months post-dose 3 | NA | NA | 56 | 32.7 (22.6–47.4) | 82.1 (69.6–91.1) | 44 | 22.9 (15.5–33.7) | 68.2 (52.4–81.4) | ||||
Serotype 3 | ||||||||||||
Baseline | 63 | 5.61 (4.89–6.45) | 4.8 (1.0–13.3) | 54 | 5.00 (NC) | 0.0 (0.0–6.6) | 65 | 5.53 (5.06–6.05) | 7.7 (2.5–17.0) | 54 | 5.00 (NC) | 0.0 (0.0–6.6) |
28 days post-dose 3 | 52 | 44.8 (31.3–64.3) | 84.6 (71.9–93.1) | 42 | 46.9 (30.9–71.2) | 85.7 (71.5–94.6) | 59 | 71.2 (53.4–94.8) | 94.9 (85.9–98.9) | 48 | 47.3 (32.5–69.0) | 85.4 (72.2–93.9) |
6 months post-dose 3 | 49 | 33.0 (23.4–46.5) | 85.7 (72.8–94.1) | 39 | 27.1 (16.6–44.3) | 71.8 (55.1–85.0) | 58 | 48.5 (36.0–65.3) | 87.9 (76.7–95.0) | 46 | 22.5 (16.3–31.0) | 71.7 (56.5–84.0) |
12 months post-dose 3 | NA | NA | 56 | 24.1 (17.6–33.0) | 73.2 (59.7–84.2) | 44 | 15.4 (11.1–21.2) | 61.4 (45.5–75.6) | ||||
Serotype 4 | ||||||||||||
Baseline | 63 | 6.55 (5.32–8.07) | 12.7 (5.6–23.5) | 54 | 5.00 (NC) | 0.0 (0.0–6.6) | 65 | 5.20 (4.81–5.63) | 1.5 (0.0–8.3) | 54 | 5.00 (NC) | 0.0 (0.0–6.6) |
28 days post-dose 3 | 52 | 51.7 (35.1–76.2) | 82.7 (69.7–91.8) | 42 | 91.8 (63.3–133) | 95.2 (83.8–99.4) | 59 | 78.5 (54.3–114) | 88.1 (77.1–95.1) | 48 | 89.2 (53.3–149) | 83.3 (69.8–92.5) |
6 months post-dose 3 | 49 | 60.0 (38.4–93.8) | 81.6 (68.0–91.2) | 39 | 98.7 (64.8–150) | 92.3 (79.1–98.4) | 58 | 39.8 (26.9–59.0) | 70.7 (57.3–81.9) | 46 | 44.3 (28.3–69.5) | 78.3 (63.6–89.1) |
12 months post-dose 3 | NA | NA | 56 | 46.9 (32.2–68.4) | 80.4 (67.6–89.8) | 44 | 48.7 (30.5–77.5) | 81.8 (67.3–91.8) | ||||